ANIK
Anika Therapeutics, Inc.NASDAQHealthcare$14.80-1.20%ClosedMarket Cap: $213.4M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.47
P/S
1.89
EV/EBITDA
-43.88
DCF Value
$3.64
FCF Yield
2.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
56.6%
Operating Margin
-9.8%
Net Margin
-9.6%
ROE
-7.4%
ROA
-5.7%
ROIC
-6.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $30.6M | 62.6% | $646.0K | $292.0K | $0.02 | — |
| FY 2025 | $112.8M | 56.6% | $-11.1M | $-10.9M | $-0.76 | — |
| Q3 2025 | $27.8M | 56.0% | $-3.2M | $-2.3M | $-0.16 | — |
| Q2 2025 | $28.2M | 50.9% | $-4.2M | $-4.0M | $-0.28 | — |
| Q1 2025 | $26.2M | 56.1% | $-4.3M | $-4.9M | $-0.34 | — |
| Q4 2024 | $-1.3M | -1749.2% | $27.8M | $-21.9M | $-1.50 | — |
| FY 2024 | $119.9M | 63.4% | $-5.1M | $-56.4M | $-3.83 | — |
| Q3 2024 | $38.8M | 3.7% | $-28.0M | $-29.9M | $-2.03 | — |
| Q2 2024 | $30.7M | 66.7% | $-1.8M | $-88.0K | $-0.01 | — |
| Q1 2024 | $40.5M | 60.8% | $-5.1M | $-4.5M | $-0.31 | — |
| Q4 2023 | $43.0M | 61.3% | $-63.8M | $-63.0M | $-4.30 | — |
| FY 2023 | $120.8M | 68.3% | $844.0K | $-82.7M | $-5.64 | — |